Eupraxia Pharmaceuticals (EPRX) Q4 2024 earnings summary

Executive summary

• Delivered compelling data from Phase 1b/2a RESOLVE trial for EP-104GI in eosinophilic esophagitis, showing improved tissue health and symptom reduction at higher doses.

• Raised C$44.5 million in a private placement, strengthening the balance sheet and funding operations into the second half of 2026.

• Published Phase 2b SPRINGBOARD trial data for EP-104IAR in knee osteoarthritis in The Lancet Rheumatology, meeting primary and most secondary endpoints.

• Announced key leadership changes, including new Chief Operating and Scientific Officer and CFO.

Financial highlights

• Net loss of $7.5 million for Q4 2024, down from $10.6 million in Q4 2023, mainly due to lower R&D and other expenses.

• Cash balance of $33.1 million as of December 31, 2024, up from $19.3 million a year earlier.

• 35,641,603 common shares and 8,905,638 preferred shares outstanding at year-end.

Outlook and guidance

• Existing cash reserves and anticipated warrant proceeds expected to fund operations through Q3 2026.

• Continued focus on advancing clinical trials for EP-104GI and EP-104IAR, with additional pipeline candidates in development.